New “Mkt Perform” Rating Was Given to Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR) Logo

Investors sentiment decreased to 0.94 in 2018 Q4. Its down 0.81, from 1.75 in 2018Q3. It fall, as 61 investors sold Nektar Therapeutics shares while 89 reduced holdings. 40 funds opened positions while 101 raised stakes. 160.47 million shares or 4.08% more from 154.18 million shares in 2018Q3 were reported.

Utah Retirement Sys holds 0.02% or 29,100 shares. 6,079 are held by Horizon Invests Lc. Sei Investments Com holds 56,014 shares. Voloridge Inv Mgmt Ltd Llc, a Florida-based fund reported 323,645 shares. Glenmede Tru Na invested in 2,634 shares. Raymond James Fincl Service has invested 0% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Zurcher Kantonalbank (Zurich Cantonalbank) reported 0.01% stake. Prudential Fin has 176,172 shares. Dekabank Deutsche Girozentrale owns 86,093 shares or 0.02% of their US portfolio. Gp One Trading L P holds 0.02% or 71,295 shares in its portfolio. Texas-based Texas Permanent School Fund has invested 0.02% in Nektar Therapeutics (NASDAQ:NKTR). Hanson Mcclain Inc holds 0% or 583 shares. Swiss Fincl Bank stated it has 0.02% in Nektar Therapeutics (NASDAQ:NKTR). Voya Investment Mngmt Limited Liability Company has invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR). Fairfield Bush And invested 0.14% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR).

Since September 19, 2018, it had 0 buys, and 11 selling transactions for $6.10 million activity. Another trade for 9,000 shares valued at $512,820 was made by Lingnau Lutz on Thursday, September 20. Another trade for 4,500 shares valued at $255,645 was sold by CHESS ROBERT. 6,515 shares were sold by Labrucherie Gil M, worth $249,199 on Friday, November 16. Nicholson John sold $228,812 worth of stock or 5,982 shares. Doberstein Stephen K had sold 4,524 shares worth $173,043 on Friday, November 16. $679,577 worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by Thomsen Jillian B. on Monday, February 4.

Why Has SVB Leerink Given Nektar Therapeutics (NASDAQ:NKTR) a $38 Price Target

In a research report revealed to investors and clients today, SVB Leerink analysts has initiated Nektar Therapeutics (NASDAQ:NKTR) coverage with “Mkt Perform” rating, and a $38 target.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Among 7 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Nektar Therapeutics has $100 highest and $47 lowest target. $74.86’s average target is 110.70% above currents $35.53 stock price. Nektar Therapeutics had 10 analyst reports since November 8, 2018 according to SRatingsIntel. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Mizuho on Tuesday, February 19. On Tuesday, November 13 the stock rating was maintained by Canaccord Genuity with “Buy”. Piper Jaffray maintained the stock with “Buy” rating in Friday, March 1 report. The firm earned “Buy” rating on Thursday, November 8 by Jefferies. The firm earned “Hold” rating on Tuesday, February 19 by H.C. Wainwright. As per Monday, March 4, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating by Mizuho given on Friday, March 1.

The stock decreased 2.18% or $0.79 during the last trading session, reaching $35.53. About 2.28M shares traded or 18.76% up from the average. Nektar Therapeutics (NASDAQ:NKTR) has declined 54.70% since March 16, 2018 and is downtrending. It has underperformed by 59.07% the S&P500.

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on May, 9. They expect $-0.62 EPS, down 3.33 % or $0.02 from last year’s $-0.6 per share. After $-0.57 actual EPS reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts 8.77 % negative EPS growth.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. The company has market cap of $6.19 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. It has a 9.4 P/E ratio. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.

More notable recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Nasdaq.com which released: “Nektar Therapeutics Becomes Oversold (NKTR) – Nasdaq” on March 06, 2019, also Nasdaq.com with their article: “BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer – Nasdaq” published on March 04, 2019, Seekingalpha.com published: “Nektar to host conference call Friday on cancer combo trial data – Seeking Alpha” on February 25, 2019. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) were released by: Seekingalpha.com and their article: “Nektar Therapeutics Q4 2018 Earnings Preview – Seeking Alpha” published on February 27, 2019 as well as Globenewswire.com‘s news article titled: “Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit — New Research Emphasizes Economic Growth – GlobeNewswire” with publication date: February 15, 2019.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.